Marc B Bierings
Overview
Explore the profile of Marc B Bierings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Admiraal R, Nierkens S, Bierings M, Belderbos M, Huitema A, Bredius R, et al.
Blood Adv
. 2025 Feb;
PMID: 39983052
Anti-thymocyte globulin (ATG) is used in pediatric allogeneic hematopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure (GF). Poor or delayed T-cell recovery, associated with increased mortality, is...
2.
Muskens K, Wieringa N, van Bergen M, Bense J, Te Pas B, de Pagter A, et al.
Blood Cancer Discov
. 2025 Jan;
6(2):110-118.
PMID: 39804695
As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies...
3.
Kalwak K, Moser L, Potschger U, Bader P, Kleinschmidt K, Meisel R, et al.
Blood Adv
. 2024 Nov;
9(4):741-751.
PMID: 39602342
The superiority of total body irradiation (TBI)-based vs chemotherapy conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukemia (ALL) has been established in the international,...
4.
Admiraal R, Versluijs A, Huitema A, Ebskamp L, Lacna A, de Kanter C, et al.
Cytotherapy
. 2024 Mar;
26(6):599-605.
PMID: 38466262
Background: Graft-versus-host disease (GvHD) and rejection are main limitations of cord blood transplantation (CBT), more so in patients with severe inflammation or previous rejections. While rigorous T-cell depletion with antithymocyte...
5.
Troullioud Lucas A, Boelens J, Prockop S, Curran K, Bresters D, Kollen W, et al.
Front Oncol
. 2023 Aug;
13:1221782.
PMID: 37649924
Background: Patients with leukemia relapse after allogeneic hematopoietic cell transplant (HCT) have poor survival due to toxicity and disease progression. A second HCT often offers the only curative treatment. Methods:...
6.
Admiraal R, Nierkens S, Bierings M, Bredius R, van Vliet I, Jiang Y, et al.
Lancet Haematol
. 2022 Feb;
9(2):e111-e120.
PMID: 35114150
Background: Anti-thymocyte globulin, which is used in the conditioning of haematopoietic stem-cell transplantation (HSCT) to prevent graft-versus-host disease (GVHD) and graft failure, has highly variable pharmacokinetics. Overexposure to anti-thymocyte globulin...
7.
Sharma A, Huang S, Li Y, Brooke R, Ahmed I, Allewelt H, et al.
Bone Marrow Transplant
. 2021 Sep;
56(12):2997-3007.
PMID: 34480120
Long-term outcomes after allogeneic hematopoietic cell transplantation (HCT) for therapy-related myeloid neoplasms (tMNs) are dismal. There are few multicenter studies defining prognostic factors in pediatric patients with tMNs. We have...
8.
Rotte L, Loeffen Y, Bierings M, Wolfs T, Lindemans C
Transplant Cell Ther
. 2021 Jun;
27(9):781.e1-781.e5.
PMID: 34153502
Data on the outcome of allogenic hematopoietic stem cell transplantation (HSCT) in pediatric patients with a history of invasive fungal infection (IFI) are limited. The aim of this study was...
9.
Sassen S, Mathot R, Pieters R, de Haas V, Kaspers G, van den Bos C, et al.
Br J Haematol
. 2021 Jun;
194(2):423-432.
PMID: 34060065
Glucocorticoids form the backbone of paediatric acute lymphoblastic leukaemia (ALL) treatment. Many studies have been performed on steroid resistance; however, few studies have addressed the relationship between dose, concentration and...
10.
Mekelenkamp H, Lankester A, Bierings M, Smiers F, de Vries M, Kars M
Pediatr Blood Cancer
. 2020 Mar;
67(5):e28229.
PMID: 32134215
Background: In pediatric hematopoietic stem cell transplantation (HSCT), the end-of-life (EOL) phase and the loss of the child is often characterized by a sudden deterioration of the child following a...